TNFRSF8 and anaplastic large cell lymphoma: In 2012, the Food and Drug Administration (FDA) approved Brentuximab vedotin (BV) for relapsed/refractory HL and anaplastic large cell lymphoma (ALCL) treatment, an anti-CD30 antibody highly expressed in this disease.